Thank you!
Your email has been successfully added to our mailing list.
CLOSE
Home
Blog
Resources
Why News Quantified Works
The Ultimate Earnings Guide
STOCK MARKET 101
About Us
Contact
Services
Institutions
Market Impact Report
Sign up
Log in
Home
Blog
Resources
Why News Quantified Works
The Ultimate Earnings Guide
STOCK MARKET 101
About Us
Contact
Services
Institutions
Market Impact Report
Log in
Sign up
×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
No thanks
Home
CAPR
Analyst Actions
CAPR –
capricor therapeutics, inc
(US:NASDAQ)
DELAYED
<
$
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
——
CAPR
SPY
QQQ
SPX
News
Earning News
Analyst Actions
SEC Filings
Date
Time
Symbol
Headline
Impact
10/31
07:46 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock.
Low
REPORT
10/24
07:49 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
Low
REPORT
10/23
08:03 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock.
Low
REPORT
10/15
06:54 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
High
REPORT
10/14
07:34 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.75 price target on the stock.
Medium
REPORT
10/11
07:24 am
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Medium
REPORT
10/8
07:15 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating.
Medium
REPORT
Live Event:
Click Here To Register For The Live Online Workshop
Latest Posts
Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day